Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$97.75 USD

97.75
409,224

+0.17 (0.17%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Is Amedisys (AMED) Up 1.8% Since Last Earnings Report?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.

Is a Surprise Coming for Amedisys (AMED) This Earnings Season?

by Zacks Equity Research

Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Higher Business Volumes Aid Teladoc (TDOC) Q4 Earnings?

by Zacks Equity Research

Teladoc Health's (TDOC) Q4 earnings are likely to reflect higher visit volumes and subscriptions, along with an increase in marketing expenses.

Amedisys (AMED) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Amedisys (AMED) to Report Q4 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark

by Zacks Equity Research

Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.

Encompass Health (EHC) Steadily Grows Inpatient Rehab Business

by Zacks Equity Research

Encompass Health (EHC) is continuously investing in post acute care services, which are in huge demand in the United States.

Sriparna Ghosal headshot

3 Biggest MedTech Trends to Watch in 2021 for Better Returns

by Sriparna Ghosal

Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.

Abbott (ABT) to Expand in Booming TBI Space on New Approval

by Zacks Equity Research

If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.

Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails

by Zacks Equity Research

Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.

Hologic (HOLX) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.

Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales

by Zacks Equity Research

The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.

AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.

Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout

by Zacks Equity Research

Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.

Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots' (WBA) fiscal first-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.

Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.

Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake

by Zacks Equity Research

The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.

Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio

by Zacks Equity Research

Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.

What Makes Amedisys (AMED) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.

Will Encompass Health (EHC) Gain From Inpatient Rehab Business?

by Zacks Equity Research

Encompass Health (EHC) is resorting to business restructuring to focus on core growth areas, which should expand its returns.

Amedisys (AMED) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Amedisys (AMED) Down 5.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amedisys (AMED) Banks on Home Health & Hospice Amid Cost Woe

by Zacks Equity Research

Amedisys (AMED) continues to benefit from the recent acquisitions of hospice care providers.